Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eleni Volakli has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of Five Host Inflammatory Biomarkers in Early Diagnosis of Ventilator-Associated Pneumonia in Critically Ill Children: A Prospective Single Center Cohort Study

    by Maria Sdougka, Maria Simitsopoulou, Elena Volakli, Asimina Violaki, Vivian Georgopoulou, Argiro Ftergioti, Emmanuel Roilides, Elias Iosifidis

    Background: Early diagnosis of ventilator-associated pneumonia (VAP) remains a challenge due to subjective clinical criteria and the low discriminative power of diagnostic tests. We assessed whether rapid molecular diagnostics in combination with Clinically Pulmonary Index Score (CPIS) scoring, microbiological surveillance and biomarker measurements of PTX-3, SP-D, s-TREM, PTX-3, IL-1β and IL-8 in the blood or lung could improve the accuracy of VAP diagnosis and follow-up in critically ill children. Methods: A prospective pragmatic study in a Pediatric Intensive Care Unit (PICU) was conducted on ventilated critically ill children divided into two groups: high and low suspicion of VAP according to modified Clinically Pulmonary Index Score (mCPIS). Blood and bronchial samples were collected on days 1, 3, 6 and 12 after event onset. Rapid diagnostics were used for pathogen identification and ELISA for PTX-3, SP-D, s-TREM, IL-1β and IL-8 measurements. Results: Among 20 enrolled patients, 12 had a high suspicion (mCPIS > 6), and 8 had a low suspicion of VAP (mCPIS < 6); 65% were male; and 35% had chronic disease. IL-1β levels at day 1 correlated significantly with the number of mechanical ventilation days (rs = 0.67, p < 0.001) and the PICU stay (r = 0.66; p < 0.002). No significant differences were found in the levels of the other biomarkers between the two groups. Mortality was recorded in two patients with high VAP suspicion. Conclusions: PTX-3, SP-D, s-TREM, IL-1β and IL-8 biomarkers could not discriminate patients with a high or low suspicion of VAP diagnosis.


  • Open Access

    Key process and outcome indicators on quality and safety of care for critically ill pediatric patients according to international standard organization protocols: a four-year follow-up study

    by Eleni Volakli, Asimina Violaki, Menelaos Svirkos, Peristera-Eleni Mantzafleri, Elpis Chochliourou, Serafeia Kalamitsou, Athanasios Kasimis, Eleni Karakeke, Parthena Georgiadou, Maria Katsafiloudi, et al.

    The European Society of Intensive Care Medicine (ESICM) suggests nine quality and safety indicators of care for critically ill patients. The aim of the present study was to examine the Key Process and Outcome Indicators (KPOIs) chosen according to International Standard Organization (ISO) protocols in a Greek Pediatric Intensive Care Unit (PICU). Two structure, one process, and four outcome indicators were examined in a stepwise approach according to Observe-Plan-Do-Study-Act (OPDSA) cycles, in an observational four-year cohort study (2017–2020). Two structure indicators—that ICUs fulfil national requirements to provide intensive care and 24-h consultant availability were requirements for the creation of the PICU and considered standards of care. One process indicator—Standardized Handover Procedure was transformed from handwritten (2017–2018) into electronic form (2019–2020) and 100% compliance rates throughout the four years were recorded. 96, 85, 103 and 94 patients were admitted in 2017, 2018, 2019 and 2020 with median (IQR) Pediatric Risk of Mortality III-24 h scores of 10 (6.25–17), 10 (6–13), 8 (5–13) and 8 (6.75–12), respectively. Mortality rates were 24%, 11.8%, 17.5%, 16%, and Standardized Mortality Ratio (SMR) were 1.42, 0.92, 1.56 and 1.33, correspondingly. No early (<48 h after PICU discharge) readmissions were recorded for 2017 and 2018, only 1 in 2019 (0.8%) and none in 2020. Catheter Related Bloodstream Infection rates were 1.37:1000, 1.37:1000, 1.26:1000 and 1.39:1000 catheter days, respectively. Unplanned extubation rate was 10.30% in 2019 and 5.72% and 3.91:1000 ventilation days in 2020. In conclusion, ISO implementation of our unit was the trigger for internal PICU audit and external benchmarking. OPDSA cycles, following small steps at a time, in an iterate cycle of evolution, facilitated our actions. The majority of the KPOIs examined in our study was within international PICUs reference values.

  • Epidemiology and outcomes of ventilator-associated events in critically ill children: Evaluation of three different definitions

    by Dimitra Papakyritsi, Elias Iosifidis, Serafia Kalamitsou, Elisavet Chorafa, Eleni Volakli, Yolanda Peña-López, Maria Sdougka, Emmanuel Roilides

    Objective: Ventilator-associated pneumonia (VAP) is one of the most common healthcare-associated infections in pediatric intensive care units (PICUs), but its definite diagnosis remains controversial. The CDC Ventilator-Associated Event (VAE) module (validated in adults) constitutes a new approach for VAP surveillance.Design: We described epidemiological characteristics of PICU VAE cases, investigated possible risk factors, and evaluated 3 different sets of diagnostic VAE criteria.Setting: This study was conducted in a PICU in a tertiary-care general hospital in northern Greece during 2017–2019.Patients: The study included patients aged 35 days–16 years who received mechanical ventilation.Methods: From medical records, we retrieved epidemiological data, clinical data, and laboratory characteristics as well as ventilator settings for our analysis. We assessed “oxygen deterioration” for the tier 1 CDC VAE module using 3 sets of diagnostic criteria: (1) CDC adult VAE criteria [increase of daily minimum fraction of inspired oxygen (FiO2) ≥ 0.2 or positive end expiratory pressure (PEEP) ≥ 3 cmH2O for 2 days], (2) the US pediatric VAE criteria [increase of FiO2 ≥ 0.25 or mean airway pressure (MAP) ≥ 4 cmH2O for 2 days], and (3) the European pediatric VAE criteria (increase of FiO2 ≥ 0.2 or PEEP ≥ 2 cmH2O for 1 day or increase of FiO2 ≥ 0.15 and PEEP ≥ 1 cm H2O for 1 day).Results: Among 326 children admitted to the PICU, 301 received mechanical ventilation. The incidence rate according to the CDC adult VAE criteria was 4.7 per 1,000 ventilator days. For the US pediatric VAE criteria the incidence rate was 6 per 1,000 ventilator days. For the European pediatric VAE criteria the incidence rate was 9.7 per 1,000 ventilator days. These results revealed statistically significant correlation of all 3 algorithms with adverse outcomes, including mortality.Conclusions: All VAE algorithms were associated with higher mortality rates. Our findings highlight the need for a unified pediatric VAE definition to improve preventive strategies.


  • Evidence and rationale for vaccinating children and adolescents against SARS-CoV-2: a comprehensive narrative review

    by Nikolaos Karantaglis, Antonios Gkantaras, Despoina Iordanidou, Eleni Volakli, Eleni Karakeke, Maria Katsafiloudi, Asimina Violaki, Maria Sdougka

    Vaccines remain the most rigorous and cost-effective weapon of the public health care system against infectious diseases. The development of safe and effective vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged as an imperative response to the unprecedented morbidity and mortality of the Coronavirus Disease 2019 (COVID-19) pandemic and the subsequent immense pressure on health care systems, families and global society. Despite the typically mild disease course of SARS-CoV-2 in minors, the associated rare but potentially life-threatening complications, as well as the emergence of new highly transmissible variants, led promptly to the extension of COVID-19 vaccine clinical trials in children and adolescents. To date, various COVID-19 vaccine candidates have been successfully trialed in pediatric populations, followed by their incorporation into corresponding vaccination campaigns in both high- and low-income countries. However, the universal COVID-19 vaccination of children and adolescents remains a matter of debate, along with skepticism about their overall safety and benefits in this age group. In this narrative review, we attempt to summarize the multi-faceted burden of COVID-19 on minors, highlighting the favourable safety/effectiveness profile of COVID-19 vaccines in this age group, elucidating the raised concerns and presenting the current implemented vaccination strategies.

  • High flow nasal cannula therapy in children: working principles and treatment failure predictors

    by Eleni Volakli, Menelaos Svirkos, Asimina Violaki, Elpis Chochliourou, Serafeia Kalamitsou, Vasiliki Avramidou, Maria Katsafiloudi, Despoina Iordanidou, Nikolaos Karantaglis, Maria Sdougka

    High Flow Nasal Cannula (HFNC) delivers high flowrates of a heated air/oxygen fresh gas breathing mixture, in an open system, at the exact amount of fraction inspired oxygen, and at the optimum hydration level. By definition, due to high flow rates, higher than 2 L/min, it produces a wash out of the anatomic dead space and the End-tidal Carbon dioxide (EtCO2), and augments thus effective alveolar ventilation at the same rate of minute ventilation, helping reduce partial arterial pressure of Carbon dioxide (PaCO2) levels. Although depending on mouth closure and the relative size of the nasal cannula prongs related to nares, it produces a minimum Positive End Expiratory Pressure (PEEP) level, which is especially helpful in keeping unstable alveoli open, recruiting lung volume, and increasing the functional residual capacity. It reduces respiratory resistance and the high work of breathing which is a common feature in patients with respiratory failure. But its most important characteristics are the ease of implementation and good patient tolerance. It has emerged as a promising support mode in the last decade, and its use is being continuously expanded. Although it started from neonates, it expanded to children and adults, and tested in all causes of acute hypoxemic respiratory failure, especially in bronchiolitis, and in post-extubation respiratory failure as well, starting from Emergency Department (ED), Pediatric Ward (PW), Pediatric Intensive Care Unit (PICU), and during transportation. Comparisons and meta-analyses, although not of equal modalities, have shown that it is definitely better than Standard Oxygen Therapy (SOT), and rather inferior to Continuous Positive Airway Pressure (CPAP). The aim of the present study is to explore the HFNC position in the timeline of recommendations for mechanical ventilation in critically ill children. We present a review on HFNC literature evidence in patients aged 1 month to 18 years, focusing on its mechanism of action, clinical effects, and timely recognition of treatment failure predictors.


  • Use of Ceftazidime-avibactam for the Treatment of Extensively drug-resistant or Pan drug-resistant Klebsiella pneumoniae in Neonates and Children <5 Years of Age

    by Elias Iosifidis, Elisavet Chorafa, Eleni Agakidou, Aggeliki Kontou, Asimina Violaki, Eleni Volakli, Eleni-Ifigeneia Christou, Charalampos Zarras, Vassiliki Drossou-Agakidou, Maria Sdougka, et al.

    Background: Emergence of extensively drug-resistant (XDR) or pan drug-resistant (PDR) Enterobacteriaceae is a major public threat especially for young patients. Treatment options for these bacteria are extremely limited with no safety data existing for neonates and children. Ceftazidime-avibactam has activity against Gram-negative bacteria producing Klebsiella pneumoniae carbapenemase, but virtually no data exist on its use in neonatal and pediatric patients. Methods: We present a single-center case series of neonates and children K. pneumoniae infections until August 2018. Medical records of patients who received ceftazidime-avibactam for at least 2 days (6 doses) were reviewed. Clinical, laboratory and microbiologic data were collected using a prestructured form. Adverse events and clinical/microbiologic responses and 15- and 30-day outcome were assessed. Results: In our case series, 8 patients (median age 53 days, range from 13 days to 4.5 years) received 9 courses of ceftazidime-avibactam at a dose of 62.5 mg/kg q8h for suspected or proven XDR/PDR K. pneumoniae infections including bloodstream infections (8 courses), central nervous system infections (2 courses) and urinary tract infection (1 course). All patients were critically ill and received other antibiotics prior and concomitantly with the administration of ceftazidime-avibactam. There was no treatment discontinuation due to adverse events. Clinical and microbiologic responses occurred in all patients, and no patient died by day 30. Conclusions: Administration of ceftazidime-avibactam appears to be well tolerated and efficacious against in vitro susceptible XDR or PDR Enterobacteriaceae without being associated with significant adverse events.


  • Open Access

    2302. Bloodstream Infections Due to Carbapenem-Resistant Gram-Negative Bacteria in Pediatric Intensive Care Unit (PICU): Risk Factors and Outcomes

    by Violetta-Magdalini Darda, Elias Iosifidis, Eleni Volakli, Charalampos Antachopoulos, Anna-Bettina Haidich, Eleni Vagdatli, Maria Sdougka, Emmanuel Roilides

    Bloodstream infections (BSI) caused by multidrug-resistant bacteria are associated with poor outcome and increased cost. We investigated risk factors for carbapenem resistance (CR) and outcome associated with the development of BSI due to Gram-negative (GN) bacteria in PICU patients, a very vulnerable population. We reviewed the records of 1 month–15 year old patients with documented GN BSI hospitalized in a PICU from 2005 to 2017. Isolates with meropenem MIC ≥16 mg/L were considered as resistant. Demographics, clinical characteristics, potential risk factors for acquisition of resistant strains, treatment, potential source control and outcome were recorded. Outcome was determined as microbiological response (negative blood cultures) within 5 days and mortality within 30 days. Both univariate and multivariable logistic regression analysis was performed and odds ratios (OR) with 95% confidence intervals (CI) were presented. 81 patients with GN BSI were studied (34.6% Pseudomonas aeruginosa, 34.6% Acinetobacter baumannii and 30.9% Enterobacteriaceae), 21 with CR isolates. Risk factors for CR BSI were: prior carbapenem use (OR: 3.86, 95% CI: 1.10, 13.82) and renal replacement therapy (OR: 3.86, 95% CI: 1.10, 13.82). In multivariable outcome analysis, high levels of CRP (OR: 0.99, 95% CI: 0.99, 0.999), renal replacement therapy (OR: 0.11, 95% CI: 0.01, 0.71) and inotrope administration (OR: 0.30, 95% CI: 0.09, 0.91) were associated with poor microbiological response, whereas source control (OR: 2.99, 95% CI: 1.01, 9.43) with better microbiological response. High PRISM score III (OR: 1.15, 95% CI: 1.04, 1.29) and CR (OR: 5.07, 95% CI: 1.47, 19.36) were both independently associated with worse outcome, whereas source control was the only independent factor preventing death (OR: 0.24, 95% CI: 0.06, 0.78). In patients with CR BSI, administration of at least two active antimicrobials was associated with better outcome (OR: 10.80, 95% CI: 1.33, 237.05). Prior carbapenem use is associated with carbapenem-resistant BSI development in PICU, which in turn is an independent risk factor for mortality. Source control is associated with better microbiological response within 5 days, as well as with decreased mortality. All authors: No reported disclosures.


  • Pharmacokinetics of Daptomycin in Critically Ill Pediatric Patients

    by Charalampos Antachopoulos, Stavroula Ilia, Paschalis Kadiltzoglou, Eirini Baira, Aristides Dokoumetzidis, Evangelos Gikas, Eleni Volakli, Maria Sdougka, George Briassoulis, Emmanuel Roilides

    The pharmacokinetics of daptomycin (10 mg/kg once daily) was studied in 4 critically ill pediatric patients aged 8 to 14 yrs. The area under the concentration-time curve from time zero to infinity (AUC 0–∞ ) of plasma concentrations on day 1 ranged between 123.8 to 663.9 μg · h/ml, with lower values observed in septic and burn patients; clearance ranged from 15.1 to 80.7 ml/h/kg. Higher-than-recommended doses of daptomycin may be needed in septic children to ensure optimal drug exposure. Interpatient variability may suggest a role for therapeutic drug monitoring.


  • Open Access

    Pharmacokinetics of Daptomycin in Pediatric Intensive Care Patients

    by Charalampos Antachopoulos, Paschalis Kadiltzoglou, Stavroula Ilia, George Briassoulis, Anastasia Geladari, Eirini Baira, Evangelos Gikas, Efstathia Mylouli, Aristides Dokoumetzidis, Eleni Volakli, et al.

    Daptomycin is a lipopeptide agent active against Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. To date, only single dose pharmacokinetics (PK) has been studied in children. We studied multiple dose PK of daptomycin administered as salvage therapy in critically ill pediatric patients. Patients hospitalized in 2 pediatric intensive care units from June 2014 to December 2016, who received daptomycin for infections caused by Gram-positive organisms not responding or intolerant to conventional antimicrobial agents and had normal renal function, were eligible for the study. Daptomycin was administered as 30-minute infusion dissolved in 50 ml normal saline at dosages decided by the treating physicians. Blood samples were collected immediately before and 30, 60, 90, 120, 240, and 360 minute after the end of First and Fifth dose. Plasma concentrations of daptomycin were determined with ultra performance liquid chromatography. An individual pharmacokinetic model was built with WinNonlin version 6.4 (Certara, Princeton, NJ) software and a two compartment structural model was fit to daptomycin concentration data over time. Four patients (2 females) of mean age 10.5 years (range: 8–14) and body weight 39 kg (range: 26–45), who received daptomycin at 10 mg/kg once daily (OD), were studied. The mean area under the curve of daptomycin concentrations at steady-state (AUC0–24) was 541.62 μg · hours/ml (range: 162.51–1001.71), with no significant differences compared with First dose. The mean clearance was 28.46 ml/hours/kg (range: 9.97–61.50), mean volume of distribution was 0.38 L/kg (range: 0.20–0.61), and mean t1/2 was 13.4 hours (range: 8.3–20.1). The observed clearance and volume of distribution of daptomycin in critically ill children of mean age 10.5 years were significantly higher than those published for healthy adult subjects. A dose of 10 mg/kg OD of daptomycin in these patients resulted in comparable drug exposure (AUC) with that of adults receiving 4 mg/kg OD. Significant inter-patient variability was observed in daptomycin clearance and AUC, which may in part be due to the altered hemodynamic status of septic patients and warrants further investigation. All authors: No reported disclosures.

  • Home mechanical ventilation registration in Greece. Preliminary results from the Hellenic HMV Network

    by Eva Serasli, Irini Lekka, Vasilis Kilintzis, Theodoros Moysiadis, Michalis Agrafiotis, Katerina Fekete, Dimitris Lagonidis, Athanasia Pataka, Kostas Porpodis, Vasiliki Paschidou, et al.

    Home Mechanical Ventilation (HMV) started in Greece during the 1990’s, however systematic registration of patients has not been attempted previously. Preliminary results derived from the implementation of a HMV registration system, applied within the Hellenic HMV Network, are presented. Methods: The HMV registration system is a flexible, on-line platform that supports recording of multi-visit patient data from multiple centers. Collected data is stored in a single data repository and can then be reviewed and exported in user defined datasets for statistical analysis. The system is based on the web server Apache, an embedded scripting language (PHP) and the open source database MySQL. Results: The Hellenic HMV Network was launched in October 2016 with the primary aim of registering current practice. Currently, 125 patients from 11 centers are registered with the following breakdown to underlying disease: 22.5% obstructive, 32.4% restrictive, 9.8% mixed (combined) lung disease, 29.4% SAS. Twenty-one % of patients are still smoking, 94.8% have clinical symptoms, 92.3% hypercapnia, 92.2% hypoxemia and 92.2% experience nocturnal hypoventilation. NIV was prescribed in 76.9% and IV via tracheostomy in 5.1%. The prescribed equipment was BPAP S (42.7%), BPAP S/T (11.1%), CPAP (25.6%) and Home Ventilators (2.6%). Conclusion: These preliminary results indicate that NIV is the preferred type of HMV. Considering the prevailing economic crisis, there is a need to expand and continue the registration recordings with the view to better understand and eventually overcome the existing problems towards implementing effective medical interventions and sustainable health policies.